On Health Suites, AstraZeneca has signed a new purchase agreement with the government of Singapore to deliver Evusheld, its long-acting antibody (LAAB) combination candidate, for the treatment of COVID-19. With the supply expected to arrive in Singapore by year end, Claressa Monteiro speaks to Vinod Narayanan, Country President, AstraZeneca Singapore, to find out more about Evusheld.

AI & Me: AI helped me write a complaint about ride cancellations. Did it work?
13:38

Viewpoint: Can Singapore remain as a trading hub if Middle East flows become unstable?
22:42

Industry Insight: Is property still a safe bet for global capital?
11:16